Peptides as NS3-serine protease inhibitors of hepatitis C virus

US7595299B2 · kind B2 · utility

Assignees

• SCHERING CORPORATION · US
• Dendreon Corporation · US

Inventors

• Anil K. Saksena · Upper Montclair, US
• Viyyoor M. Girijavallabhan · Parsippany, US
• Stephane L. Bogen · Somerville, US
• Raymond G. Lovey · West Caldwell, US
• Edwin Jao · Hackettstown, US
• Frank Bennett · Piscataway, US
• Jinping McCormick · Edison, US
• Haiyan Wang · Cranbury, US
• Russell E. Pike · Stanhope, US
• Yi Liu · San Diego, US
• Tin-Yau Chan · Edison, US
• Zhaoning Zhu · Plainsboro, US
• Ashok Arasappan · Bound Brook, US
• Kevin X. Chen · Edison, US
• Srikanth Venkatraman · Fords, US
• Tejal Parekh · Mountain View, US
• Patrick A. Pinto · Mine Hill, US
• Bama Santhanam · Bound Brook, US
• F. George Njoroge · Hackettstown, US
• Ashit K. Ganguly · Upper Montclair, US
• Henry A. Vaccaro · South Plainfield, US
• Scott Jeffrey Kemp · San Diego, US
• Odile Esther Levy · San Diego, US
• Marguerita Lim-Wilby · Village of La Jolla, US
• Susan Y. Tamura · San Diego, US

Key dates

• Filing date: Mar 24, 2005
• Grant date: Sep 29, 2009
• Expiry date: Jun 22, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K7/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention discloses novel peptide compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.